| Title |
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
|
|---|---|
| Published in |
BMC Cancer, May 2009
|
| DOI | 10.1186/1471-2407-9-161 |
| Pubmed ID | |
| Authors |
Eva Juengel, Johanna Engler, Iyad Natsheh, Jon Jones, Ausra Mickuckyte, Lukasz Hudak, Dietger Jonas, Roman A Blaheta |
| Abstract |
Treatment options for metastatic renal cell carcinoma (RCC) are limited due to resistance to chemo- and radiotherapy. The development of small-molecule multikinase inhibitors has now opened novel treatment options. We evaluated the influence of the receptor tyrosine kinase inhibitor AEE788, applied alone or combined with the mammalian target of rapamycin (mTOR) inhibitor RAD001, on RCC cell adhesion and proliferation in vitro. |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 23 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 25% |
| Student > Ph. D. Student | 6 | 25% |
| Student > Bachelor | 4 | 17% |
| Student > Master | 2 | 8% |
| Student > Doctoral Student | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 3 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 46% |
| Agricultural and Biological Sciences | 4 | 17% |
| Biochemistry, Genetics and Molecular Biology | 3 | 13% |
| Veterinary Science and Veterinary Medicine | 1 | 4% |
| Unknown | 5 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 July 2011.
All research outputs
#7,454,951
of 22,790,780 outputs
Outputs from BMC Cancer
#2,059
of 8,294 outputs
Outputs of similar age
#37,752
of 111,881 outputs
Outputs of similar age from BMC Cancer
#17
of 46 outputs
Altmetric has tracked 22,790,780 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,294 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,881 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.